

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**


# Cell-Specific Adenovirus

Fig. 1A



2/42

Fig. 1B



3/42

# Taxol (0.625 nM) + CV787 (MOI=0.01)




Fig. 2

4/42

Taxotere (3.12 nM) + CV787 (moi=0.01)




Fig. 3

5/42

# CV787 (moi=0.01) + Taxotere (3.12nM)




Fig. 4

6/42

# Mitoxantrone (100 nM) + CV787 (moi=0.1)





Fig. 5

7/42

Etoposide (500 ng/ml) + CV787 (moi=0.01)



Treatment Fig. 6



# CV787 (moi=0.01) + Doxorubicin (50 ng/ml)

8/42




Fig. 7

9/42

# Cisplatin (8.25 $\mu$ M) + CV787 (moi=0.1)




Fig. 8

FOUO 2547860

# 5-Fluorouracil (35 $\mu$ M) + CV787 (moi=0.01)

10/42




Fig. 9

# CV787 (moi=0.01) + $^{137}\text{Cs}$ (2 Gy)

11/42




Fig. 10

12/42

# Virus Yield (LNCaP)




Fig. 11

13/42




Fig. 12

14/42

# Taxol Does not Alter CV787's Specificity




Fig. 13

Days After Treatment

—■— 293 —●— LNCaP —▲— HBL-100 —◆— OVCAR-3

15/42

Specificity of CV787 + Mitoxantrone




FIG. 14



# CV790 0.01moi/Doxorubicin 10ng/ml

16/42




Fig. 15

17/42

10ng/ml Doxorubicin first,  
 then 0.01 MOI CV790




Fig. 16

18/42

# 0.01 MOI CV790 and 10ng/ml Doxorubicin together




Fig. 17

19/42

# CV790 0.1moi/Cisplatin 1ug/ml




Fig. 18

20/42

CV790 0.1moi/Taxol 0.5ng/ml




Fig. 19

# CV790 0.1moi/5-FU 10ng/ml

21/42




Fig. 20

22/42

# CV790 0.1moi/Mitoxantrone 4ng/ml




Fig. 21

# CV790 0.1moi/Mitomycin C 10ng/ml

23/42




Fig. 22



24/42

# Tumor Volume of LNCaP Xenograft Treated with CV787 and Taxol




Fig. 23

Weeks After Treatment

—◆— Control —△— CV787, 10<sup>7</sup>p/mm<sup>3</sup> —●— Taxol, 15 mg/kg —■— CV787/Taxol

25/42




Fig. 24

# Tumor Volume of LNCaP Xenograft Treated with CV787 and Taxol




Fig. 25

# Tumor Volume of LNCaP Xenograft Treated with CV787 and Mitoxantrone

27/42




Fig. 26

# Tumor Volume of LNCaP Xenografts Treated with CV787 and Estramustine




Fig. 27

29/42

# LNCaP Xenograft Treated with CV787 and Docetaxel




Fig. 28

Weeks After Treatment

30/42

# LNCaP Xenograft Treated with CV787 and Docetaxel




Fig. 29

31/42

# Tumor Volume of Hep3B Treated with CV790 and Doxorubicin




Fig. 30



32/42

# Tumor Volume of Hep3B Xenograft Treated with CV890 and Doxorubicin





Fig. 31

33/42

# Cell Viability

## Radiation (6Gy) + CV787(moi=0.1)



Days After Treatment

- ◇— No treatment
- Radiation
- CV787
- Radiation+CV787

Fig. 32

34/42




Fig. 33

35/42





Fig. 34

36/42

# Virus Yield Radiation (6Gy) + CV787(moi=0.1)




Days After Treatment

—●— CV787    —■— Radiation+CV787

Fig. 35

37/42



38/42

# FIG. 37

G ATG ACC GGC TCA ACC ATC GCG CCC ACA ACG GAC TAT CGC AAC ACC  
 46  
 Met Thr Gly Ser Thr Ile Ala Pro Thr Thr Asp Tyr Arg Asn Thr  
 1 5 10 15  
 ACT GCT ACC GGA CTA ACA TCT GCC CTA AAT TTA CCC CAA GTT CAT GCC  
 94  
 Thr Ala Thr Gly Leu Thr Ser Ala Leu Asn Leu Pro Gln Val His Ala  
 20 25 30  
 TTT GTC AAT GAC TGG GCG AGC TTG GAC ATG TGG TGG TTT TCC ATA GCG  
 142  
 Phe Val Asn Asp Trp Ala Ser Leu Asp Met Trp Trp Phe Ser Ile Ala  
 35 40 45  
 CTT ATG TTT GTT TGC CTT ATT ATT ATG TGG CTT ATT TGT TGC CTA AAG  
 190  
 Leu Met Phe Val Cys Leu Ile Ile Met Trp Leu Ile Cys Cys Leu Lys  
 50 55 60  
 CGC AGA CGC GCC AGA CCC CCC ATC TAT AGG CCT ATC ATT GTG CTC AAC  
 238  
 Arg Arg Arg Ala Arg Pro Pro Ile Tyr Arg Pro Ile Ile Val Leu Asn  
 65 70 75  
 CCA CAC AAT GAA AAA ATT CAT AGA TTG GAC GGT CTG AAA CCA TGT TCT  
 286  
 Pro His Asn Glu Lys Ile His Arg Leu Asp Gly Leu Lys Pro Cys Ser  
 80 85 90 95  
 CTT CTT TTA CAG TAT GAT TAA  
 307  
 Leu Leu Leu Gln Tyr Asp  
 100

09814357 "101501

39/42




Fig. 38






Fig. 39

41/42




Fig. 40

FIG. 40

# Structure of CV876, CV882 and CV884

42/42




Fig. 41